Rallybio Corp (RLYB)

03:11 AM

Rallybio advances Phase 2 trial for rare pregnancy condition By Investing.com - Investing.com Canada

03:11 AM

Nov 27, 2024

Rallybio Flat On Release Of New Findings - MENAFN.COM

Nov 27, 2024

Nov 27, 2024

Rallybio Flat on Release of New Findings - Baystreet.ca

Nov 27, 2024

Nov 27, 2024

Rallybio advances Phase 2 trial for rare pregnancy condition - Investing.com

Nov 27, 2024

Nov 27, 2024

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women - Business Wire

Nov 27, 2024

Nov 26, 2024

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference - Marketscreener.com

Nov 26, 2024

Nov 25, 2024

Rallybio's SWOT analysis: rare disease biotech stock advances FNAIT treatment - Investing.com

Nov 25, 2024

Nov 25, 2024

Rallybio to Host Key Webcast on RLYB116 C5 Inhibitor Development Updates | RLYB Stock News - StockTitan

Nov 25, 2024

Nov 22, 2024

Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women - MSN

Nov 22, 2024

Nov 21, 2024

Rallybio Launches Phase 2 Trial for Groundbreaking Pregnancy Treatment RLYB212 | RLYB Stock News - StockTitan

Nov 21, 2024

Nov 15, 2024

Rallybio stock hits 52-week low at $0.96 amid market challenges - Investing.com India

Nov 15, 2024

Nov 13, 2024

FMR LLC Acquires Shares in Rallybio Corp - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

HC Wainwright Issues Pessimistic Forecast for Rallybio (NASDAQ:RLYB) Stock Price - Defense World

Nov 12, 2024

Nov 08, 2024

Staff cuts help New Haven-based biotech Rallybio reduce 3Q loss - Hartford Business Journal

Nov 08, 2024

Nov 08, 2024

Rallybio Co. (NASDAQ:RLYB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Nov 08, 2024

Nov 07, 2024

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates - BioSpace

Nov 07, 2024

Nov 07, 2024

Rallybio Narrows Losses 37%, Advances RLYB212 Trial with $75M Cash Runway | RLYB Stock News - StockTitan

Nov 07, 2024

Nov 05, 2024

Two former Alexion leaders fight through a tough market to maintain a rare disease biotech - PharmaVoice

Nov 05, 2024

Nov 05, 2024

Two former Alexion leaders fight through a tough market to sustain a rare disease biotech - BioPharma Dive

Nov 05, 2024

Oct 30, 2024

Rallybio stock plunges to 52-week low at $0.99 amid market challenges - Investing.com Canada

Oct 30, 2024

Oct 30, 2024

Rallybio advances novel FNAIT prevention trial By Investing.com - Investing.com Canada

Oct 30, 2024

Oct 29, 2024

Rallybio advances novel FNAIT prevention trial - Investing.com India

Oct 29, 2024

Oct 29, 2024

Rallybio stock plunges to 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved - TipRanks

Oct 29, 2024

Oct 29, 2024

Rallybio to Begin First Clinical Trial for Prevention of Rare Pregnancy Blood Disorder - Femtech Insider

Oct 29, 2024

Oct 29, 2024

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT - Business Wire

Oct 29, 2024

Oct 23, 2024

Rallybio stock hits 52-week low at $1.08 amid market challenges - Investing.com Australia

Oct 23, 2024

Oct 14, 2024

Rallybio stock plunges to 52-week low at $1.08 amid market challenges - Investing.com

Oct 14, 2024

Oct 01, 2024

Rallybio shares hold Buy rating on HPP treatment data - Investing.com India

Oct 01, 2024

Sep 30, 2024

Rallybio's SWOT analysis: FNAIT treatment stock poised for growth amid challenges - Investing.com

Sep 30, 2024

Sep 30, 2024

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting - StockTitan

Sep 30, 2024

Sep 24, 2024

Rallybio reveals higher FNAIT risk across populations By Investing.com - Investing.com Australia

Sep 24, 2024

Sep 23, 2024

Rallybio reveals higher FNAIT risk across populations - Investing.com

Sep 23, 2024

Sep 23, 2024

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting - Business Wire

Sep 23, 2024

Sep 19, 2024

Rallybio Co. (NASDAQ:RLYB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Sep 19, 2024

Sep 18, 2024

Rallybio announces board member resignation - Investing.com

Sep 18, 2024

Sep 17, 2024

Rallybio announces board member resignation By Investing.com - Investing.com UK

Sep 17, 2024

Sep 17, 2024

Dr. Kush Parmar Steps Down from Rallybio’s Board and Committee - TipRanks

Sep 17, 2024

Sep 17, 2024

Rallybio Corporation Announces Resignation of Kush Parmar as Member of Board and Chair of Nominating and Corporate Governance Committee, Effective October 31, 2024 - Marketscreener.com

Sep 17, 2024

Sep 12, 2024

RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan

Sep 12, 2024

Sep 10, 2024

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit - Business Wire

Sep 10, 2024

Sep 09, 2024

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree - Business Wire

Sep 09, 2024